Criteria to give antiplatelet in ischemic stroke
Reading File
Finding Sources
Searching PubMed
"ischemic stroke" AND "antiplatelet" AND "criteria"
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have rich, comprehensive information from Harrison's 22nd edition. Let me compile the full answer.
Antiplatelet Therapy in Ischemic Stroke - Indications and Criteria
1. Acute Ischemic Stroke (Non-thrombolysis patients)
Indication: Aspirin should be given to ALL patients with acute ischemic stroke who do NOT receive thrombolytic therapy (IV tPA/tenecteplase).
- Aspirin 325 mg orally within 24-48 hours of onset is the standard first-line agent.
- It reduces early recurrent stroke and improves outcomes (IST and CAST trials).
- If tPA is given: Antiplatelet therapy is deferred for 24 hours to reduce the risk of hemorrhagic transformation.
2. Minor Ischemic Stroke / High-Risk TIA - DUAL Antiplatelet Therapy (DAPT)
This is where criteria matter most. DAPT is indicated when:
| Criterion | Detail |
|---|---|
| NIHSS 0-5 (minor stroke, non-disabling deficit) | Neurologically mild presentation |
| Onset within 24 hours | Must be initiated early |
| No cardioembolic source (e.g., no Afib) | Anticoagulation preferred if cardioembolic |
| No indication for systemic anticoagulation | Hypercoagulable states, prosthetic valves, etc. |
Regimen (21-day DAPT then monotherapy):
- Aspirin 81 mg + Clopidogrel (300-600 mg loading dose, then 75 mg/day) for 21 days, then aspirin monotherapy
- OR Aspirin 81 mg + Ticagrelor (180 mg load, then 90 mg twice daily) for 21-30 days, then aspirin monotherapy
Key trial evidence:
- CHANCE trial (Chinese patients, TIA or minor stroke within 24 h): Clopidogrel + aspirin reduced 90-day stroke risk from 11.7% to 8.2% vs. aspirin alone (p<0.001)
- POINT trial (international, NIH-sponsored): Confirmed similar results
- Important caveat: Benefit of clopidogrel-based DAPT is reduced or absent in patients carrying the CYP2C19 loss-of-function polymorphism (common in Asian populations). Ticagrelor is not affected by this polymorphism and may be preferred in those at risk.
3. When Antiplatelet is NOT the Right Choice
| Scenario | Preferred treatment instead |
|---|---|
| Cardioembolic stroke (Atrial fibrillation) | Oral anticoagulation (e.g., apixaban 5 mg BD) |
| Mechanical heart valve | Warfarin (INR 2.5-3.5) |
| Hypercoagulable state (antiphospholipid syndrome, etc.) | Anticoagulation |
| Patent foramen ovale (PFO) with cryptogenic stroke | Endovascular closure + antiplatelet |
| Significant intracranial atherosclerosis | Antiplatelet + aggressive risk factor control |
| Patient already on anticoagulation | Continue anticoagulation; do NOT add antiplatelet long-term |
4. Long-term Secondary Prevention (Monotherapy)
After the 21-day DAPT course (for minor stroke/TIA), switch to single antiplatelet agent:
- Aspirin 81 mg/day - most widely used
- Clopidogrel 75 mg/day - marginally more effective than aspirin (CAPRIE trial); preferred if aspirin intolerant
- Aspirin + extended-release dipyridamole (Aggrenox) - equivalent alternative to clopidogrel
Long-term DAPT is NOT recommended (MATCH, CHARISMA, SPS3 trials all showed no benefit over monotherapy but increased bleeding risk, including hemorrhagic death).
5. Stroke Etiology Determines Antiplatelet Eligibility
The underlying mechanism guides therapy:
| Stroke Mechanism | Antiplatelet? |
|---|---|
| Large-vessel atherosclerosis | Yes - DAPT short-term, then monotherapy |
| Small vessel (lacunar) stroke | Yes - monotherapy (SPS3 showed DAPT harmful long-term) |
| Cryptogenic stroke | Yes - antiplatelet pending investigation |
| Cardioembolic (Afib, prosthetic valve) | No - anticoagulate |
| Cervical artery dissection | Either antiplatelet or anticoagulation (similar efficacy per 2024 meta-analysis, PMID 38847098) |
Summary Algorithm
- Hemorrhagic stroke ruled out (non-contrast CT) → proceed
- Is patient eligible for tPA/thrombectomy?
- Yes → treat, defer antiplatelets 24h
- No → start antiplatelet immediately
- Is there a cardioembolic source (Afib, valvular)?
- Yes → anticoagulate (not antiplatelet)
- No → antiplatelet
- Is it a minor stroke (NIHSS 0-5) or TIA within 24h?
- Yes → DAPT (aspirin + clopidogrel OR ticagrelor) for 21 days, then monotherapy
- No (moderate/severe stroke) → aspirin monotherapy
Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 438 - Cerebrovascular Diseases
When to give dapt and when to give single antiplatelet in pt with. Stroke
Based on the previous research from Harrison's 22nd Edition, I can answer this directly and comprehensively.
DAPT vs. Single Antiplatelet in Ischemic Stroke
Give DAPT When:
| Criterion | Specifics |
|---|---|
| Minor ischemic stroke | NIHSS 0-5 (non-disabling deficit) |
| High-risk TIA | ABCD² score ≥4, or symptomatic intracranial/extracranial stenosis, or DWI-positive TIA |
| Time window | Initiated within 24 hours of symptom onset |
| No cardioembolic source | No Afib, no prosthetic valve, no mural thrombus |
| No indication for anticoagulation | No hypercoagulable state, no DVT/PE |
| No recent thrombolysis | If tPA given, wait 24h before any antiplatelet |
DAPT Regimen:
- Aspirin 81 mg + Clopidogrel (600 mg load → 75 mg/day) for 21 days
- OR Aspirin 81 mg + Ticagrelor (180 mg load → 90 mg BD) for 21-30 days
- Then switch to monotherapy after 21-30 days
Basis: CHANCE trial (90-day stroke reduced 11.7% → 8.2%), POINT trial (international replication)
Note on CYP2C19: If the patient is of Asian descent or known CYP2C19 poor metabolizer, prefer ticagrelor over clopidogrel (ticagrelor is not affected by this polymorphism).
Give SINGLE Antiplatelet When:
| Scenario | Agent of Choice |
|---|---|
| Moderate-to-severe stroke (NIHSS >5) | Aspirin 81-325 mg/day |
| After completing 21-day DAPT course | Aspirin 81 mg OR clopidogrel 75 mg (monotherapy) |
| Large-vessel atherosclerotic stroke (long-term) | Aspirin or clopidogrel |
| Small vessel / lacunar stroke (long-term) | Aspirin or clopidogrel monotherapy (SPS3 trial: long-term DAPT = no benefit + ↑ bleeding) |
| Cryptogenic stroke (no source found) | Aspirin or clopidogrel |
| Post-PFO closure | Aspirin 81 mg post-closure |
| Aspirin-intolerant patients | Clopidogrel 75 mg/day |
| Alternative to clopidogrel | Aspirin + extended-release dipyridamole (Aggrenox) |
Do NOT Give Antiplatelet (Use Anticoagulation):
- Atrial fibrillation → apixaban, rivaroxaban, or warfarin
- Mechanical heart valve → warfarin (INR 2.5-3.5)
- Antiphospholipid syndrome → warfarin
- Hypercoagulable states (Protein C/S deficiency, Factor V Leiden) → anticoagulation
Quick Decision Tree
Ischemic stroke confirmed (no hemorrhage on CT)
|
Is there a cardioembolic source (Afib, valve)?
YES → Anticoagulate (NOT antiplatelet)
NO ↓
Was tPA/thrombolysis given?
YES → Wait 24h, then start aspirin monotherapy
NO ↓
NIHSS 0-5 AND onset <24h AND no anticoagulation indication?
YES → DAPT for 21 days → then monotherapy
NO → Single antiplatelet (aspirin 81-325 mg)
↓
After 21 days of DAPT:
→ Switch to aspirin OR clopidogrel monotherapy (long-term)
Why NOT Long-term DAPT?
Three major trials showed long-term (>30 days) DAPT causes harm without added benefit:
| Trial | Finding |
|---|---|
| MATCH | DAPT vs. clopidogrel alone - no stroke reduction, ↑ major bleeding (3% vs. 1%) |
| CHARISMA | DAPT vs. aspirin alone - no benefit in prior stroke/TIA group |
| SPS3 | DAPT vs. clopidogrel alone in lacunar stroke - ↑ hemorrhage + ↑ death |
The short-term DAPT window (21 days) captures the high-risk early recurrence period without excess bleeding risk.
Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025)
If nisha more than 5 and onset after 24 hour what to give
Finding Sources
Searching PubMed
"ischemic stroke" AND "antiplatelet" AND "moderate severe"
Finding Sources
Reading File
Reading File
Here is the focused answer for this exact scenario:
NIHSS > 5 AND Onset > 24 Hours: What to Give?
Short Answer: Single Antiplatelet (Aspirin monotherapy)
Both criteria that qualify for DAPT are missed:
- NIHSS > 5 = not a minor stroke
- Onset > 24h = outside the DAPT time window
So DAPT is not indicated. The patient receives single antiplatelet therapy for secondary prevention.
Regimen
| Step | Drug | Dose |
|---|---|---|
| Initial load | Aspirin | 325 mg once |
| Maintenance (long-term) | Aspirin | 81 mg/day |
| If aspirin intolerant | Clopidogrel | 75 mg/day |
| Alternative | Aspirin + extended-release dipyridamole (Aggrenox) | once daily |
All three options (aspirin, clopidogrel, aspirin+dipyridamole) are considered equally acceptable for long-term secondary prevention. Choice depends on tolerability, cost, and patient adherence.
One Important Exception: Intracranial Atherosclerosis
If imaging (MRA/CTA) reveals significant intracranial arterial stenosis as the stroke mechanism, even with NIHSS > 5, Harrison's recommends:
- Aspirin 81 mg + Clopidogrel 75 mg for 3 months (then aspirin monotherapy)
This is because intracranial atherosclerosis carries a very high early recurrence risk, and the SAMMPRIS trial data support short-term DAPT in this subgroup.
What About Anticoagulation?
Even in this scenario, rule out cardioembolic source first:
| If found | Treatment |
|---|---|
| Atrial fibrillation | Oral anticoagulation (apixaban preferred), NOT antiplatelet |
| No cardioembolic source confirmed | Continue single antiplatelet |
| ESUS (Embolic Stroke of Undetermined Source) | Aspirin - trials of DOACs (rivaroxaban, dabigatran) failed to show superiority over aspirin in ESUS |
Summary in One Line
NIHSS > 5 + onset > 24h + no cardioembolic source = Aspirin 325 mg load, then 81 mg/day long-term (single antiplatelet)
Sources: Harrison's Principles of Internal Medicine, 22nd Edition (2025); Fuster & Hurst's The Heart, 15th Edition
This is a shared conversation. Sign in to Orris to start your own chat.